TransCode Therapeutics Announces $1.2M Registered Direct Offering Of Common Stock Priced At-The-Market Under Nasdaq Rules
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities